Converting a Liability to an Asset: Using the Clearance of a Malaria Parasite Protein from the Blood of Infected Subjects to Predict the Outcome of Treatment.

07:00 EST 6th December 2017 | BioPortfolio

Summary of "Converting a Liability to an Asset: Using the Clearance of a Malaria Parasite Protein from the Blood of Infected Subjects to Predict the Outcome of Treatment."

No Summary Available


Journal Details

This article was published in the following journal.

Name: The Journal of infectious diseases
ISSN: 1537-6613


DeepDyve research library

PubMed Articles [11352 Associated PubMed Articles listed on BioPortfolio]

Plasmodium protein UIS3 protects the parasite from autophagy clearance.

The malaria causative parasite, Plasmodium, has received intense focus due to its complex life cycle and threat to human health. When infecting human hepatocytes, the parasite manages to escape cleara...

Repurposing drugs to target the malaria parasite unfolding protein response.

Drug resistant Plasmodium falciparum parasites represent a major obstacle in our efforts to control malaria, a deadly vector borne infectious disease. This situation creates an urgent need to find and...

Recent advances on T-cell exhaustion in malaria infection.

T-cell exhaustion reportedly leads to dysfunctional immune responses of antigen-specific T cells. Investigations have revealed that T cells expand into functionally defective phenotypes with poor reca...

Evaluation of malaria multiplex/nested PCR performance at low parasite densities and mixed infection in Iran: A country close to malaria elimination.

Malaria is still a major public health problem in subtropical and tropical regions. The rapid and accurate diagnosis of malaria remains a challenge in most of the endemic areas. The primary objective ...

Intra-host dynamics of co-infecting parasite genotypes in asymptomatic malaria patients.

Malaria-infected individuals often harbor mixtures of genetically distinct parasite genotypes. We studied intra-host dynamics of parasite genotypes co-infecting asymptomatic adults in an area of inten...

Clinical Trials [3683 Associated Clinical Trials listed on BioPortfolio]

Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites

The purpose of this study is to provide a new drug combination for a better treatment of P. falciparum for a faster parasite clearance and to counteract artemisinin resistance.

Phase II Dose Ranging Study of Artesunate

The purpose of this study is to compare four regimens using US FDA GMP intravenous artesunate for the treatment of uncomplicated Plasmodium falciparum malaria to identify the most effectiv...

Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia

The primary goal of this study is to quantify the benefit of adding artesunate to amodiaquine in treating patients with uncomplicated P. falciparum malaria, in a low transmission area in C...

Safety and Protective Efficacy of Pb(PfCS@UIS4)

In the underlying study, a genetically modified P. berghei parasite is used. P. berghei is one of the four Plasmodium species that causes malaria in rodents. The hypothesis is that immuniz...

The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau

The National Malaria Programme in Guinea-Bissau recommends paracetamol for all children treated for malaria. We, the investigators of the Bandim Health Project, want to evaluate whether th...

Medical and Biotech [MESH] Definitions

A protozoan parasite that causes vivax malaria (MALARIA, VIVAX). This species is found almost everywhere malaria is endemic and is the only one that has a range extending into the temperate regions.

A protozoan parasite that occurs naturally in the macaque. It is similar to PLASMODIUM VIVAX and produces a type of malaria similar to vivax malaria (MALARIA, VIVAX). This species has been found to give rise to both natural and experimental human infections.

A protozoan parasite that causes avian malaria (MALARIA, AVIAN), primarily in chickens, and is transmitted by the Aedes mosquito.

A protozoan parasite that occurs primarily in subtropical and temperate areas. It is the causal agent of quartan malaria. As the parasite grows it exhibits little ameboid activity.

A biguanide compound which has little antimalarial activity until metabolized in the body to the active antimalarial agent cycloguanil. The usefulness of proguanil is limited by the rapid development of drug resistance by the malarial parasite. The hydrochloride is used for the casual prophylaxis of falciparum malaria, to suppress other forms of malaria, and to reduce transmission of infection (From Martindale, The Extra Pharmacopoeia, 30th ed, p405)

Quick Search


DeepDyve research library

Relevant Topics

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Searches Linking to this Article